Actemra 400 MG/20 ML vial 20ML
Ended Awarded
- Contract number
- SPE2DB26FZQ79
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $5,313
Award facts
- Contract value 100% obligated
- $5,313.27 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $5,313.27 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Actemra 400 mg/20 ml vials. The contract, issued on October 21, 2025, with an ultimate completion date of November 12, 2025, utilizes firm fixed-price pricing with no set-aside designation. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which carries a $499,999,999 ceiling value through December 31, 2036.
The PPV-G GEN V program represents a comprehensive $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors capable of supplying a full spectrum of pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group's established performance across numerous delivery orders demonstrates its capability to fulfill diverse pharmaceutical requirements for military medical operations. The company's product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, positioning it as a critical supplier within the federal pharmaceutical supply chain serving the Defense Logistics Agency's Medical Supply Chain division without identified subcontractor relationships.
Quick answers
Who was awarded contract SPE2DB26FZQ79?
SPE2DB26FZQ79 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 21, 2025.
How much is contract SPE2DB26FZQ79 worth?
The government has obligated $5,313 on SPE2DB26FZQ79.
Is contract SPE2DB26FZQ79 an order under another contract?
Yes. SPE2DB26FZQ79 is a delivery order under SPE2DB22D9244, an indefinite delivery contract.
Was contract SPE2DB26FZQ79 competed?
The extent of competition for SPE2DB26FZQ79 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award